Can we manage arterial hypertension without hydrochlorothiazide?


Cite item

Full Text

Abstract

Currently we have accumulated considerable experience of hydrochlorothiazide use in hypertensive patients justifying substantially decrease of risk of cardiovascular complications. The article discusses clinical studies confirming the advisability of hydrochlorothiazide use in patients with hypertension, as well as ways to prevent adverse events associated with its use, including type 2 diabetes mellitus

About the authors

V V Fomin

V V Fomin

References

  1. Shah S.U., Anhjum S., Littler W.A. Use of diuretics in cardiovascular disease: (2) hypertension. Postgrad Med. J. 2004;80:271-276.
  2. Chalmers J., MacMahon S., Manchia G. et al. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin. Exp. Hypertens. 1999;21(5-6):1009-1060.
  3. ESH-ESC Guidelines Committee. ESH-ESC guidelines for the management of arterial hypertension. J. Hypertens. 2003;21:1011-1053.
  4. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC VI Report. J.A.M.A. 2003;289:2560-2571.
  5. Секция артериальной гипертонии ВНОК. Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (второй пересмотр). М., 2004.
  6. The ALLHAT Officers and Coordinators. Major cardiovascular events in hypertensive patients randomized to doxasozin versus chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J.A.M.A. 2000;283(15):1967-1975.
  7. ESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J. Hypertens. 2007;25:1105-1187.
  8. Российское Медицинское общество по артериальной гипертонии - Всероссийское научное общество кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр). М., 2008.
  9. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vs diuretic: The Antihypertensive an Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). J.A.M.A. 2002;288:2981-2997.
  10. Wright J.T. Jr., Dunn J.K., Cutler J.A. et al.; ALLHAT Collaborative Research Group. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. J.A.M.A. 2005;293(13):1595-1608.
  11. Dahlof B., Sever P.S., Poulter N.R. et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
  12. Barzilay J.I., Davis B.R., Cutler J.A., et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med. 2006;166:2191-2201.
  13. Elliott W.J., Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201-207.
  14. Carter B.L., Einhorn P.T., Brands M., et al. Thiazide-induced dysglycemia; call for research from a working group from the national heart, lung and blood institute. Hypertension 2008;52:30-36.
  15. Zillich A.J., Garg J., Basu S., et al. Thiazide diuretics, potassium and the development of diabetes. A quantative review. Hypertension 2006;48:219-224.
  16. Shafi T., Appel L.J., Miller E.R. III et al. Changes in serum potassium mediates thiazide-induced diabetes. Hypertension 2008;52:1022-1029.
  17. Franse L.V., Pahor M., Di Bari M., et al Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000;35:1025-1030.
  18. Reffelmann T., Kloner R.A. Sexual function in hypertensive patients receiving treatment. Vasc Health Risk Manag. 2006;2(4):447-455.
  19. Pickkers P., Hughes A.D., Russel F.G.M., et al. Thiazide-induced potassium vasodilation in humans is mediated by potassium channel activation. Hypertension 1998;32:1071-1076.
  20. Kostis J.B., Wilson A.C., Freudenberger R.S., et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am. J. Cardiol. 2005;95:29-35.
  21. SHEP Cooperative Research Study Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. J.A.M.A. 1991;265:3255-3264.
  22. Sutton-Tyrrell K., Wildman R., Newman A., et al. Extent of cardiovascular risk reduction associated with treatment of isolated systolic hypertension. Arch. Intern. Med. 2003;163:2728-2731.
  23. Ramakrishna G., Schechter C.B., Phillips R. Diagnosis and treatment of isolated systolic hypertension in the elderly: results of a survey four years post-SHEP. Am. J. Geriatr. Cardiol. 1997;6:21-36.
  24. Ferrucci L., Furberg C.D., Penninx B.W., et al. Treatment of isolated systolic hypertension is most effective in older patients with high-risk profile. Circulation 2001;104:1923-1926.
  25. Taylor J. The hypertension detection and follow-up program: a progress report. Circ. Res. 1977;40(5 Suppl. 1):I106-I109.
  26. Hypertension Detection and Follow-up Program Cooperative Group Five-year findings of the hypertension detection and follow-up program. II. Mortality by race-sex and age. Hypertension Detection and Follow-up Program Cooperative Group. J.A.M.A. 1979;242(23):2572-2577.
  27. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. J.A.M.A. 1979;242(23):2562-2571.
  28. Langford H.G., Blaufox M.D., Oberman A., et al. Return of hypertension after withdrawal of prolonged antihypertensive therapy, effect of weight loss, sodium reduction, and baseline factors. Trans. Assoc. Am. Physicians. 1984;97:190-196.
  29. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. III. Reduction in stroke incidence among persons with high blood pressure. J.A.M.A. 1982;247(5):633-638.
  30. Mascioli S.R., Grimm R.H. Jr., Neaton J.D., et al. Characteristics of participants at baseline in the Treatment of Mild Hypertension Study (TOMHS). Am. J. Cardiol. 1990;66(9):32C-35C.
  31. Liebson P.R., Grandits G.A., Dianzumba S., et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 1995;91(3):698-706.
  32. Weir M.R., Flack J.M., Applegate W.B. Tolerability, safety, and quality of life and hypertensive therapy: the case for low-dose diuretics. Am. J. Med. 1996;101(3A):83S-92S.
  33. Grimm R.H. Jr., Grandits G.A., Cutler J.A., et al. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch. Intern. Med. 1997;157(6):638-648.
  34. Grimm R.H. Jr., Flack J.M., Grandits G.A., et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group. J.A.M.A. 1996;275(20):1549-1556.
  35. Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертонии // Сердце. 2005. Т. 4(3). С. 120-126.
  36. Neutel J.M., Saunders E., Bakris J.L. et al. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J. Clin Hypertens. (Greenwich). 2005;7(7):395-400.
  37. Sowers J.R., Neuten J.M., Saunders E., et al. Antihypertnensive efficacy of irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J. Clin. Hypertens. 2006;8:470-480.
  38. Kintscher U., Bramlage P., Paar W.D., et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc. Diabetol. 2007;6:12.
  39. Bleich M., Greger R. Mechanism of action of diuretics. Kidney Int. 1997;51(Suppl. 59):S11-S15.
  40. Langford H.G., Curb J.D., Pressel S., et al. Effect of thiazide-based therapy on serum alkaline phosphatase. Hypertension Detection and Follow-up Group. J. Hum. Hypertens. 1991;5(4):333-338.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies